

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Peter S. Hendricks

eRA COMMONS USER NAME (credential, e.g., agency login): phendricks

POSITION TITLE: University Professor

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Virginia, Charlottesville VA	B.A.	05/1998	Psychology/Sociology
University of South Florida, Tampa FL	M.A.	05/2003	Clinical Psychology
Durham VA Medical Center	Intern	06/2006	Clinical Psychology
University of South Florida, Tampa FL	Ph.D.	06/2006	Clinical Psychology
San Francisco Treatment Research Center, University of California, San Francisco	Postdoctoral Fellowship	06/2010	Substance Abuse Treatment Research

A. Personal Statement

I am a University Professor and clinical psychologist with a longstanding interest in addiction. I am particularly interested in the development of novel and more efficacious interventions for substance use disorders and comorbid conditions, with an emphasis on vulnerable populations and mechanisms of change.

I also have a longstanding interest in psychedelics, including their use in clinical settings, potential therapeutic applications and risks, epidemiology, and effects on brain functioning. I am currently completing the first randomized controlled trial of psilocybin in the treatment of cocaine use disorder—a trial that includes assessment of resting state functional connectivity—and I serve as site PI of a NIDA-funded study of psilocybin in the treatment of tobacco dependence (U01DA052174-01A1). Furthermore, I am PI of a randomized controlled trial of psilocybin in the treatment of fibromyalgia—a trial that also includes a brain imaging component—and a randomized controlled trial of very low doses or “microdoses” of psilocybin in the treatment of demoralization. I am therefore ideally positioned to successfully complete the proposed project focused on mechanisms of change in psilocybin-assisted treatment for cocaine use disorder.

1. Dourron, H.M., Strauss, C., & **Hendricks, P.S.** (2022). Self-Entropic Broadening theory: Toward a new understanding of self and behavior change informed by psychedelics and psychosis. *Pharmacological Reviews*, 74, 984-1029.
2. Ortiz, C.E., Dourron, H.M., Sweat, N.W., Garcia-Romeu, A., MacCarthy, S., Anderson, B.T., & **Hendricks, P.S.** (2022). Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. *Neuropharmacology*, 214, 109127.
3. Johnson, M.W., **Hendricks, P.S.**, Barrett, & Griffiths, R.R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacology & Therapeutics*, 197, 83-102.
4. **Hendricks, P.S.** (2018). Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. *International Review of Psychiatry*, 4, 331-342.

Projects I would like to highlight:

U01DA052174-01A1

Johnson (PI); Role: Site PI for UAB

12/1/21-11/30/24

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Diamond Therapeutics

Hendricks (PI)

10/1/23-10/1/25

Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health

CTN-0109 CURB-2

Trivedi (PI); Role: Site PI for UAB

7/1/22-2/29/24

Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Beckley PsyTech

Role: Site PI for UAB

A Quadruple Masked, Dose-finding Study to Evaluate the Safety and Efficacy of Intranasal BPL-003 [5-MeO-DMT] in Patients with Treatment-Resistant Depression

R01 DA045186-01A1

Hendricks (PI)

07/01/19-06/30/24

Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation

B. Positions and Honors

Positions and Employment

2023-	University Professor, Department of Psychiatry, University of Alabama at Birmingham
2020-2023	Professor, Department of Health Behavior, University of Alabama at Birmingham
2015-2020	Associate Professor, Department of Health Behavior, University of Alabama at Birmingham.
2010-2015	Assistant Professor, Department of Health Behavior, University of Alabama at Birmingham.
2006-2010	Postdoctoral Fellow, San Francisco Treatment Research Center, University of California San Francisco.
1999-2006	Graduate Research Assistant, Tobacco Research and Intervention Program at the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida.
1996-1998	Undergraduate Research Assistant, Drs. D. Wegner and B. DePaulo, University of Virginia.

Other Experiences and Professional Memberships

2023-	Editor-in-Chief, Psychedelic Medicine
2020-	Co-founder, Center for Addiction and Pain Prevention and Intervention
2006-	Association for Psychological Science
2006-	College on Problems of Drug Dependence
1999-	Society for Research on Nicotine and Tobacco
1999-	American Psychological Association (Divisions 28 and 50)

Honors

2007-2010	National Institutes of Health Loan Repayment Program Award
-----------	------------------------------------------------------------

C. Contribution to Science

1. Potential therapeutic applications of psilocybin and other psychedelics. I have explored the potential therapeutic applications of psilocybin and other psychedelics with a focus on substance use disorders and comorbid conditions (e.g., chronic pain).

1. Schindler, E.A.D., & **Hendricks, P.S.** (2023). Adapting psychedelic medicine for headache and chronic pain disorders. *Expert Review of Neurotherapeutics*, 23, 867-882.
2. **Hendricks, P.S.**, Copes, H., Family, N., Williams, L.T., Luke, D., & Raz, S. (2022). Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. *Journal of Psychopharmacology*, 36, 337-347.
3. Yaden, D.B., Berghella, A.P., Regier, P.S., Garcia-Romeu, A., Johnson, M.W., & **Hendricks, P.S.** (2021). Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. *International Journal of Drug Policy*, 98, 103380.
4. **Hendricks, P.S.** (2014). Back to the future: A return to psychedelic treatment models for addiction. *Journal of Psychopharmacology*, 28, 981-982.

2. Potential risks associated with psychedelic use. I am interested in better understanding the potential risks associated with psychedelic use. Characterizing these risks informs clinical investigation as well as public health strategies in the wake of psychedelic legalization.

1. Simonsson, O., Goldberg, S.B., Chambers, R., Osika, W., Simonsson, C., & **Hendricks, P.S.** (2023). Psychedelic use and psychiatric risks. *Psychopharmacology* [online ahead of print]. doi: 10.1007/s00213-023-06478-5.
2. Simonsson, O., **Hendricks, P.S.**, Chambers, R., Osika, W., & Goldberg, S.B. (2023). Prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics. *Journal of Affective Disorders*, 326, 105-110.
3. Grossman, D.H., & **Hendricks, P.S.** (2022). Shedding light on classic psychedelics and self-harm. *Journal of Clinical Psychiatry*, 18, 83(2): 21com14268.
4. Johnson, M.W., Griffiths, R.R., **Hendricks, P.S.**, & Henningfield, J.E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. *Neuropharmacology*, 142, 143-166.

3. Epidemiology of psychedelic use. I have studied the epidemiology of psychedelic use, including population-level associations with mental health outcomes and criminal behavior. These studies inform future therapeutic applications, including in criminal justice populations.

1. Simonsson, O., Osika, W., Carhart-Harris, R., & **Hendricks, P.S.** (2021). Associations between lifetime classic psychedelic use and cardiometabolic diseases. *Scientific Reports*, 11: 14427.
2. **Hendricks, P.S.**, Crawford, M.S., Cropsey, K.L., Copes, H., Sweat, N.W., Walsh, Z., & Pavela, G. (2018). The relationships of classic psychedelic use with criminal behavior in the United States adult population. *Journal of Psychopharmacology*, 32, 37-48.
3. **Hendricks, P.S.**, Thorne, C.B., Clark, C.B., Coombs, D.W., & Johnson, M.W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *Journal of Psychopharmacology*, 29, 280-288.
4. **Hendricks, P.S.**, Clark, C.B., Johnson, M.W., Fontaine, K.R., Cropsey, K.L. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. *Journal of Psychopharmacology*, 28, 62-66.

Complete list of published works

<http://www.ncbi.nlm.nih.gov/pubmed/?term=hendricks+ps>